UK Markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
136.41-1.90 (-1.37%)
At close: 04:00PM EST
135.00 -1.41 (-1.03%)
After hours: 05:52PM EST
Full screen
Trade prices are not sourced from all markets
Previous close138.31
Open130.20
Bid128.00 x 800
Ask136.36 x 1300
Day's range130.00 - 137.92
52-week range125.08 - 212.00
Volume1,164,719
Avg. volume831,991
Market cap16.315B
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-7.13
Earnings date09 Feb 2022 - 14 Feb 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est209.55
  • Business Wire

    Alnylam Presents Positive 18-Month Results from HELIOS-A Phase 3 Study of Investigational Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

    CAMBRIDGE, Mass., January 21, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis, met all secondary endpoints measured at 18 months in patients with hATTR amyloidosis with polyneuropathy, including statistically significant improvements in neuropathy impairment, quality of life (QoL

  • Business Wire

    Alnylam to Present Full 18-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran at the Société Francophone du Nerf Périphérique Annual Meeting

    CAMBRIDGE, Mass., January 14, 2022--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present full 18-month results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis, at the Société Francophone du Nerf Périphérique (SFNP) Annual Meeting. The meeting will be held January 21-22 in Pa

  • Bloomberg

    Alnylam’s CEO Is Ready to Take Over From a Biotech Legend

    (Bloomberg) -- Yvonne Greenstreet was sitting on a plane at Boston Logan International Airport waiting to take off in 2018 when U.S. regulators approved Alnylam Pharmaceuticals Inc.’s first drug, Onpattro. The chief operating officer grabbed her carry-on from the overhead bin, ran off the plane and bolted to the office so she could celebrate the accomplishment with her colleagues. Most Read from BloombergCypriot Scientist Says Deltacron Covid Variant Isn’t ErrorWorld’s Biggest Crypto Fortune Beg